Continuous subcutaneous foslevodopa/foscarbidopa improves off time in Parkinson's disease; severe adverse events higher in prior DBS group
Patients with Parkinsons disease who had prior brain surgery saw more side effects while using new skin patches
This post hoc analysis of an open-label phase 3 trial evaluated continuous subcutaneous infusion of foslevodopa/foscarbidopa in 244 patients…
A new look at trial data shows skin patches help Parkinsons patients move better and sleep longer. However, those who had brain surgery earl…
